Less resource intensive 505(b) (2) pathway remains a feasible path, similar to what Opana had before they pulled out is potentially achievable for us?
Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-3
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(25.0%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $5.442K | 2.674M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 43236745 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 44431350 | 23 |
View Market Depth
| Last trade - 10.00am 02/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |